CONTEXT: International Classification of Diseases-9/10 codes for chronic cough (CC) do not exist, limiting investigation. OBJECTIVE: To develop a computerized algorithm to determine CC prevalence and its characteristics. DESIGN: This observational study using administrative data identified hierarchically patients aged 18 to 85 years with CC from 2013 to 2016. First, a specialist-diagnosed CC group was identified using an internal CC encounter code during an outpatient visit to a pulmonologist, allergist, otolaryngologist, or gastroenterologist. Subsequently, an event-diagnosed CC group was identified based on clinical notes through natural language processing, ICD-9/ICD-10 cough codes, and dispensed antitussives. MAIN OUTCOME MEASURES: Prevalence of CC and comparison of clinical characteristics between specialist-diagnosed and event-diagnosed CC subgroups. RESULTS: A total of 50,163 patients with CC of more than 8 weeks were identified. Of these, 11,290 (22.5%) were specialist diagnosed, and 38,873 (77.5%) were event diagnosed. The CC cohort was 57.4 ± 16.5 years of age; 67.6% were female. The overall prevalence was 1.04% (95% confidence interval = 1.03-1.06) in 2016. Prevalence in 2016 was higher in female patients (1.21%) than in male patients (0.81%), higher in patients aged 65 to 85 years (2.2%) than in patients aged 18 to 44 years (0.43%), and higher in Blacks (1.38%) than in Whites (1.21%). Compared with patients with event-diagnosed CC, patients with specialist-diagnosed CC exhibited significantly higher frequencies of laboratory tests and respiratory and nonrespiratory comorbidities and dispensed medication and lower frequency of pneumonia, all-cause and respiratory-cause emergency department visits and hospitalizations, and dispensed antitussives. CONCLUSIONS: We identified a CC cohort using electronic data in a managed care organization. Prevalences varied by sex, age, and ethnicity. Clinical characteristics varied between specialist-diagnosed and event-diagnosed CC.
CONTEXT: International Classification of Diseases-9/10 codes for chronic cough (CC) do not exist, limiting investigation. OBJECTIVE: To develop a computerized algorithm to determine CC prevalence and its characteristics. DESIGN: This observational study using administrative data identified hierarchically patients aged 18 to 85 years with CC from 2013 to 2016. First, a specialist-diagnosed CC group was identified using an internal CC encounter code during an outpatient visit to a pulmonologist, allergist, otolaryngologist, or gastroenterologist. Subsequently, an event-diagnosed CC group was identified based on clinical notes through natural language processing, ICD-9/ICD-10 cough codes, and dispensed antitussives. MAIN OUTCOME MEASURES: Prevalence of CC and comparison of clinical characteristics between specialist-diagnosed and event-diagnosed CC subgroups. RESULTS: A total of 50,163 patients with CC of more than 8 weeks were identified. Of these, 11,290 (22.5%) were specialist diagnosed, and 38,873 (77.5%) were event diagnosed. The CC cohort was 57.4 ± 16.5 years of age; 67.6% were female. The overall prevalence was 1.04% (95% confidence interval = 1.03-1.06) in 2016. Prevalence in 2016 was higher in female patients (1.21%) than in male patients (0.81%), higher in patients aged 65 to 85 years (2.2%) than in patients aged 18 to 44 years (0.43%), and higher in Blacks (1.38%) than in Whites (1.21%). Compared with patients with event-diagnosed CC, patients with specialist-diagnosed CC exhibited significantly higher frequencies of laboratory tests and respiratory and nonrespiratory comorbidities and dispensed medication and lower frequency of pneumonia, all-cause and respiratory-cause emergency department visits and hospitalizations, and dispensed antitussives. CONCLUSIONS: We identified a CC cohort using electronic data in a managed care organization. Prevalences varied by sex, age, and ethnicity. Clinical characteristics varied between specialist-diagnosed and event-diagnosed CC.
Authors: A H Morice; G A Fontana; A R A Sovijarvi; M Pistolesi; K F Chung; J Widdicombe; F O'Connell; P Geppetti; L Gronke; J De Jongste; M Belvisi; P Dicpinigaitis; A Fischer; L McGarvey; W J Fokkens; J Kastelik Journal: Eur Respir J Date: 2004-09 Impact factor: 16.671
Authors: Richard S Irwin; Michael H Baumann; Donald C Bolser; Louis-Philippe Boulet; Sidney S Braman; Christopher E Brightling; Kevin K Brown; Brendan J Canning; Anne B Chang; Peter V Dicpinigaitis; Ron Eccles; W Brendle Glomb; Larry B Goldstein; LeRoy M Graham; Frederick E Hargreave; Paul A Kvale; Sandra Zelman Lewis; F Dennis McCool; Douglas C McCrory; Udaya B S Prakash; Melvin R Pratter; Mark J Rosen; Edward Schulman; John Jay Shannon; Carol Smith Hammond; Susan M Tarlo Journal: Chest Date: 2006-01 Impact factor: 9.410
Authors: Michael Schatz; Robert S Zeiger; David Mosen; Andrea J Apter; William M Vollmer; Thomas B Stibolt; Albin Leong; Michael S Johnson; Guillermo Mendoza; E Francis Cook Journal: J Allergy Clin Immunol Date: 2005-11-08 Impact factor: 10.793
Authors: Alyn H Morice; Eva Millqvist; Maria G Belvisi; Kristina Bieksiene; Surinder S Birring; Kian Fan Chung; Roberto W Dal Negro; Peter Dicpinigaitis; Ahmad Kantar; Lorcan P McGarvey; Adalberto Pacheco; Raimundas Sakalauskas; Jaclyn A Smith Journal: Eur Respir J Date: 2014-08-19 Impact factor: 16.671